anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: Perianal fistulising Crohn's disease (pfCD) is a distinct and debilitating phenotype seen in around one-third of patients with CD. Clinical trials in pfCD are increasingly using magnetic resonance imaging (MRI) criteria as a primary endpoint, but there is heterogeneity in the radiological definition of a healed perianal fistula that currently limits our ability to perform meaningful meta-analyses of studies. Our aim is to standardise outcomes through the generation of an international consensus definition of a radiologically healed fistula.
METHODS AND ANALYSIS: This international Delphi consensus study employs a two-part strategy.The first is a systematic review to identify a longlist of variables used to define radiological healing in pfCD. MRI-based indices used to score fistula severity and healing will be assessed for their methodological quality using Consensus-based Standards for the selection of health Measurement Instruments (COSMIN). The systematic review protocol will be conducted using COSMIN methodology and reported using Preferred Reporting Items for Systematic Reviews and Meta-Analyses.The second part will be an online Delphi consensus, guided by the results of the systematic review. Radiologists, gastroenterologists and colorectal surgeons with expertise in the management of pfCD will be invited to take part in two to three rounds of online surveys. Once an a priori threshold of >80% agreement is reached on individual radiological components used to define 'healing' and 'healed', a final meeting of key stakeholders will be organised to generate a consensus definition of a healed fistula.
ETHICS AND DISSEMINATION: The study has been deemed exempt from a formal Research Ethics Committee review as no patients will participate directly in the consensus process, given the technical nature of the research question. The study is registered with the local R&D department (Reference RD24/007). Publication of this study will help standardise radiological endpoint measurement in clinical trials of pfCD and improve the synthesis and meta-analysis of comparative studies.
PROSPERO REGISTRATION NUMBER: CRD42024504334.
SYnapse TENS device will be used for alleviating pain through electrical stimulation. This is a battery powered device where an electrical current is applied intra-orally on the buccal and lingual sides using an intra-oral pad applicator. This device has been cleared for marketing by the Food and Drug Administration (FDA) and the prescribed electrical field falls almost a 10 factor level lower than routine pulp testing devices used in dentistry. The TENS device was previously tested in a pilot study with promising results. Chair side application and at-home use of the device by the patient was shown to drastically reduce pain and discomfort associated with orthodontic tooth movement.
Lifestyle intervention will consist of a structured intervention in a specific alimentary plan (carbohydrates: 40-45%; fats: 25-35% \[saturated fats \<7% monounsaturated fats up to 20% and polyunsaturated fats \<10% \] and proteins: 15-20%), which will be repeated in each review. Also, be recommended to increase daily physical activity, setting a target walking 10,000 steps a day. To do this, to patients assigned to this treatment arm, will be provided with a pedometer and will asked to fill out a form with the steps that they walked each day. At each visit, the distance walked will be reviewed and the target set will be remarked.
ADC will be measured in the same subject in the wake state (following a night of regular sleep) and during sleep (following a night of sleep deprivation). The MRI scans will be done in the morning (9 AM-12 pm), once while the subject is sleeping (following a night of sleep deprivation) and once while awake (following regular sleep 9 AM 12 PM).
The Honey standard of care group will receive treatment as usual, alternating acetaminophen and ibuprofen with a PRN three-day supply of opioid analgesic, plus 1 tsp of honey with every dose of acetaminophen. The Honey standard of care group will receive the first dose of honey in the recovery room with the administration of acetaminophen and will be provided with honey upon discharge.
The invention relates to the technical field of plant medicines, relates to preparation and application of daphne giraldii nitsche active total flavonoids, and particularly relates to an extraction method of the active total flavonoids in daphne giraldii nitsche and application of the total flavonoids in preparation of anti-liver cancer medicines. The invention is prepared by the following method: pulverizing dried stem bark of Daphne giraldii Nitsche, and extracting with ethanol under reflux. Concentrating the extractive solution under reduced pressure until the concentrated solution has no ethanol smell. The concentrated solution was extracted with ethyl acetate and n-butanol in this order and the extracts were combined. And (3) performing polyamide column chromatography and silica gel column chromatography on the combined extract to obtain the daphne giraldii active total flavone. The invention also provides a pharmaceutical composition which comprises the daphne giraldii active total flavone. The daphne giraldii nitsche active total flavonoids and the pharmaceutical composition thereof prepared by the invention have obvious anti-liver cancer effect and can be used for preparing anti-liver cancer drugs.
OBJECTIVES: Although in epilepsy patients the likelihood of becoming seizure-free decreases substantially with each unsuccessful treatment, to our knowledge this has been poorly investigated in status epilepticus (SE). We aimed to evaluate the proportion of SE cessation and functional outcome after successive treatment steps.
METHODS: We conducted a post hoc analysis of a prospective, observational, multicenter cohort (Sustained Effort Network for treatment of Status Epilepticus [SENSE]), in which 1049 incident adult SE episodes were prospectively recorded at nine European centers. We analyzed 996 SE episodes without coma induction before the third treatment step. Rates of SE cessation, mortality (in ongoing SE or after SE control), and favorable functional outcome (assessed with modified Rankin scale) were evaluated after each step.
RESULTS: SE was treated successfully in 838 patients (84.1%), 147 (14.8%) had a fatal outcome (36% of them died while still in SE), and 11 patients were transferred to palliative care while still in SE. Patients were treated with a median of three treatment steps (range 1-13), with 540 (54.2%) receiving more than two steps (refractory SE [RSE]) and 95 (9.5%) more than five steps. SE was controlled after the first two steps in 45%, with an additional 21% treated after the third, and 14% after the fourth step. Likelihood of SE cessation (p < 0.001), survival (p = 0.003), and reaching good functional outcome (p < 0.001) decreased significantly between the first two treatment lines and the third, especially in patients not experiencing generalized convulsive SE, but remained relatively stable afterwards.
SIGNIFICANCE: The significant worsening of SE prognosis after the second step clinically supports the concept of RSE. However, and differing from findings in human epilepsy, RSE remains treatable in about one third of patients, even after several failed treatment steps. Clinical judgment remains essential to determine the aggressiveness and duration of SE treatment, and to avoid premature treatment cessation in patients with SE.
PURPOSE:To provide the titled food containing at least one kind of charred powder of Hirudo (a kind of leech), Tabanus (a kind of gadfly) or Eupolyphaga (a kind of cockroach), and effective to prevent various dermatic diseases, hyperlipemia, arterio-sclerosis, etc. CONSTITUTION:The objective food for lowering blood viscosity and effective to prevent the congestion caused by the increse in neutral fat and cholesterol in blood and the increase in blood viscosity, by using at least one kind of charred powder of Hirudo (e.g. Whitmania pigra WHITMAN, Whitmania acranulata, Hirudo nipponia WHITMAN, etc.), Tabanus (e.g. Tabanus yao Macq, Hybomitra montana Meigen, Tabanus trigonus Coquilette, etc.) or Europhaga (e.g. Eupolyphaga sinensis WALKER, Opisthoplatio orientalis BURMEISTER, etc.) as essential component. It is administered at a dose of 50-1,000mg, preferably 500mg of the charred powdeer per head. The leech and cockroach are washed with water, put into an unglazed earthen vessel and charred by heating from outside in closed state. The gadfly is dried inn the sun or in the shade and charred in the same manner as above after removing the head, legs, etc.
The remote intervention group is designed for reducing the chances of person-to-person contact response to the current COVID-19 pandemic and development of digital internet. It uses innovative technology combining wearable devices with inertial measurement units, blue-tooth equipment, apps, feedback technology and artificial intelligence based remote comprehensive training programs.
A kind of manufacturing method for the prills of 0.1 to 1.5mm in diameter with uniform shapes. The prills comprise a pharmaceutically active substance selected from the derivative of ketoprofen and meprobamate. The substance exhibits an indefinite crystallization point due to supercool effect. The method includes melting 40 to 80% of the active substance and 20 to 60% of pharmaceutical excipient promoting the solidification of the active substance for preparation of a kind of mixture in molten form. Then to mix or melt the mixture of active substance and pharmaceutical excipient and extrude the melted mixture produced from the vibrated nozzle ( the nozzle comprises a high frequency electronic vibration system to produce a 500 to 10,000 Hz vibration for prills forming ) that the prills formed are allowed to fall in a tower countercurrentwise to a gas from the height of 1m to 10m and solidified the active substance and excipient. Then the solid prills are collected.
AIMS: Renal fibrosis is a common feature in various chronic kidney diseases (CKD). Tubular cell damage is a main characterization which results from dysregulated fatty acid oxidation (FAO) and lipid accumulation. Cannabinoid Receptor 2 (CB2) contributes to renal fibrosis, however, its role in FAO dysregulation in tubular cells is not clarified. In this study, we found CB2 plays a detrimental role in lipid metabolism in tubular cells.
METHODS: CB2 knockout mice were adopted to establish a folic acid-induced nephropathy (FAN) model. CB2-induced FAO dysfunction, lipid deposition, and fibrogenesis were assessed in vivo and vitro. To explore molecular mechanisms, β-catenin inhibitors and peroxisome proliferator-activated receptor alpha (PPARα) activators were also used in CB2-overexpressed cells. The mediative role of β-catenin in CB2-inhibited PPARα and peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1α) activation was analyzed.
RESULTS: CB2 activates β-catenin signaling, resulting in the suppression of PPARα/PGC-1α axis. This decreased FAO functions and led to lipid droplet formation in tubular cells. CB2 gene ablation effectively mitigated FAO dysfunction, lipid deposition and uremic toxins accumulation in FAN mice, consequently retarding renal fibrosis. Additionally, inhibition to β-catenin or PPARα activation could greatly inhibit lipid accumulation and fibrogenesis induced by CB2.
CONCLUSIONS: This study highlights CB2 disrupts FAO in tubular cells through β-catenin activation and subsequent inhibition on PPARα/PGC-1α activity. Targeted inhibition on CB2 offers a perspective therapeutic strategy to fight against renal fibrosis.
<P>PROBLEM TO BE SOLVED: To provide lactobacillus suppressing the increase uric acid levels in blood and suitable to food/drink and pharmaceutical applications.  <P>SOLUTION: Various kinds of lactobacillus are cultured in the presence of a purine body, the consumption level of the purine body and the production level of the purine body's decomposed product are measured, thereby multiple kinds of lactobacillus remarkable in the ability to decompose the purine body are selected. These multiple kinds of lactobacillus are orally administered to rats raised with purine body-containing feed, and the rats' ordinary state and serum uric acid levels are measured. Based on the results, the influence on the serum uric acid levels by the lactobacillus administration is examined. As a result, Lactobacillus gasseri OLL2959 and Lactobacillus oris OLL2779, two kinds of lactobacillus that significantly suppress the serum uric acid levels, are found.  <P>COPYRIGHT: (C)2008,JPO&INPIT
With the development of brain-computer interface industry, large amounts of related applications have entered people's vision. BCI applications based on steady-state visual evoked potentials (SSVEP) are widely used because they do not require pre-training and have high information transmission rates. However, in the actual use of SSVEP stimulus paradigm, the subjects will produce visual fatigue with the use, and fatigue will affect the transmission efficiency. In this experiment, an experimental environment consisting of two paradigm stimulus frequencies (7.5 Hz, 15 Hz), three resolutions (800 × 600, 1280 × 720, 1920 × 1080) and three refresh rates (120 Hz, 240 Hz, 360 Hz) is set up. The Likert scale is used to collect subjective fatigue and preference scores, and the EEG acquisition system and eye tracker are used to collect objective data. Using the proposed information entropy-CRITIC algorithm to combine subjective and objective indicators, a fatigue assessment system (display screen fitness-DSF) is innovated to score different experimental environments. The higher the DSF score, the better the visual experience. The results show that when using the 7.5 Hz SSVEP paradigm, the combination of 360 Hz and 1920 × 1080 can bring the best visual experience. When using the 15 Hz SSVEP paradigm, the combination of 240 Hz and 1280 × 720 is the best. DSF provides powerful help for hardware and software selection guidance and vision protection when using SSVEP-based BCI applications.
A medical ontology may be used for computer assisted clinical decision support. Multi-level and/or semantically grouped medical ontology is incorporated into a machine learning algorithm. The resulting machine-learnt algorithm outputs information to assist in clinical decisions. For example, a patient record is input to the algorithm. Based on the incorporated medical ontology, similarities are aggregated in different groups. An aggregate similarity of at least one group is a function of an aggregate similarity of at least another group. One or more similar patients and/or outcomes are identified based on similarity. Probability based outputs may be provided.
Eligible patients receive vaccination with tumor antigen pulsed autologous monocyte-derived mature dendritic cells with a fixed interval. The dendritic cells are generated from leukapheresis products and frozen after antigen loading.

HLA A2 positive patients are treated with PADRE and oncopeptide pulsed DC; survivin and telomerase peptides. HLA A2 negative patients are treated with KLH and tumorlysate pulsed DC; autologous or allogeneic. Each patient is given 6 immunizations with at least 5x106 peptide/lysate pulsed autologous DC. Vaccination 1-4 is given weekly and 4-6 at 2-week intervals. Those patients who exhibit stable disease, partial response or complete response after 6 injections will be given 4 more vaccinations at 2-week interval. The vaccine is applied by intradermal injection near the inguinal region. IL-2 2 MIU s.c. day 2-6 and Thymosin alpha 1 (Zadaxin®, SciClone) 1,6 mg s.c. twice a week are used for adjuvants. Scans and re-staging tests are performed at scheduled intervals throughout the study.
The invention relates to a traditional Chinese medicine composite for treating horse gastroenteric catarch, which is characterized that active components comprise the following raw materials in parts by weight: 25-35 parts of cinnamon, 50-70 parts of glycyrrhiza, 50-70 parts of green chiretta and 25-35 parts of zeolite powder. The optimization scheme of various raw materials is as follows: 30 parts of cinnamon, 60 parts of glycyrrhiza, 60 parts of green chiretta and 30 parts of zeolite powder. The granularity of the cinnamon, the glycyrrhiza, the green chiretta and the zeolite powder is ranged from 20 meshes to 200 meshes. The invention takes detoxication, toxicant expulsion, dampness elimination and pain relief as therapeutic principles, has the advantages of reasonable composing prescription, simple preparation technology, wide source of Chinese herbal medicine components, low cost, no medicine residue, no toxic and side effects and easy absorption by animals, combines frigotherapy and pyretotherapy, eliminates dampness, warming spleen, fulfills the remarkable functions of detoxication, repulsing toxicant, eliminating the dampness, relieving pains and regulating body functions, efficiently treats the horse gastroenteric catarch and shortens a recovery period. When applied, the invention is taken according to 0.5g/kg by body weight. Proved by a clinical test, the traditional Chinese medicine composite has unique curative effect and high curative rate above 90 percent.
Methods for treating obsessions and/or compulsions are described. In one method, ondansetron or a pharmaceutically acceptable salt thereof is administered to a patient suffering from obsessions and/or compulsions for more than seven days. The ondansetron or pharmaceutically acceptable salt thereof may be administered as a pharmaceutically effective dose up to about 1.5 mg (free-base equivalent). In another method, a serotonin reuptake inhibitor (SRI) and ondansetron or a pharmaceutically acceptable salt thereof is administered to a patient suffering from obsessions and/or compulsions. The method may optionally include the step of administering a serotonin reuptake inhibitor to the patient. Additionally or alternatively, the method may also include the step of administering a neuroleptic to the patient.
INTRODUCTION: Bariatric surgery, an option for obesity management, can significantly alter gastrointestinal structure and processes. These changes can impact the pharmacokinetics (PK) of medications, which can translate to clinical differences in efficacy and safety. Chronic pain is prevalent in obesity and often persists post-bariatric surgery.
AREAS COVERED: This narrative review examines the PubMed literature from 1990 to January 2024 for the impact of bariatric surgery on the management of chronic pain medications including non-opioid (acetaminophen, non-steroidal anti-inflammatory drugs, antidepressants, and cannabinoids) and opioid medications.
EXPERT OPINION: An individualized medication management approach is ideal for post-bariatric surgery patients, as PK parameters, type of surgery, time since surgery, and patient-specific factors make it difficult to support blanket recommendations. Close monitoring of efficacy and safety outcomes is essential in chronic pain management. While the PK of acetaminophen and opioids are impacted, the value of these medications in the setting of chronic pain is dwindling as more efficacy and safety data emerges. A life-long ban of NSAIDs due to marginal ulcer risk is not endorsed; rather, we advocate for shifting the focus to marginal ulcer prevention strategies, individualized benefit-risk analysis, and safety monitoring using surrogate markers.
Subjects received standard topotecan with the addition of bevacizumab. Cycles were 28 days and continued until toxicity, progression or subject wish to discontinue treatment. Topotecan administered 4 mg/m2 IV on days 1, 8 and 15 and bevacizumab IV 10 mg/kg, days 1 and 15 of each cycle.
Scald is a common skin injury in daily life. It is well known that skin burns are associated with inflammation and oxidative stress. In our previous study, we found that Abelmoschus manihot (L.) medik had excellent therapeutic effects on scald-induced inflammation, but its effect on scald-induced oxidative stress was not reported. In this study, a deep second-degree scald model in mice was established, and the wound healing rate, healing time, malondialdehyde (MDA) and total superoxide dismutase (T-SOD) levels, and nuclear factor erythroid 2-related Factor 2 (Nrf2) expression in wound tissue were measured to evaluate the scald wound healing performance of extraction from A. manihot (L.) medik (EAM). Scalding activity in mice was examined in vivo by hot water-induced finger swelling. The treatment scald activities were also examined in vivo by subjecting mice to thermal water-induced digit swelling. Additionally, the antioxidant effect of EAM on fibroblasts was also used to determine the mechanism in vitro. The results showed that EAM not only decreased the wound healing time but also effectively regulated the levels of oxidising, MDA and T-SOD in wound tissue. Concurrently, EAM suppressed digit swelling and hyperalgesia. Furthermore, EAM had a significant protective effect on NIH-3T3 cells after H2 O2 injury by regulating the Nrf2 signalling pathway against oxidative injury. Therefore, EAM is a promising drug for the treatment of scald-induced inflammation.
PURPOSE: To obtain a self-disinfecting impression material comprising a powdery disinfectant such as a phenol derivative without transfer of a pathoghenic microorganism from a patient suffering from diseases in teeth through an impression. CONSTITUTION: This self-disinfecting impression material comprises a hydrocolloid, a gelling agent, a retarder, a filler, an additive and a disinfectant. An irreversible hydrocolloid such as an alginate or agar is preferred as the hydrocolloid. The disinfectant is preferably a phenol derivative (e.g. 2- isopropyl-5-methylphenol) or a quaternary ammonium compound having 1-100μm (preferably 5-40μm) particle diameter. The amount thereof added is 0.05-1.0 pt.wt. based on 100 pts.wt. impression material. The powdery disinfectant is initially premixed with the filler in an amount of 1-50 times based on the disinfectant and then added and mixed through a sieve having 150-400μm sieve opening in the other starting materials in a mixer when producing the impression material. Disinfection, etc., affecting dimensional compatibility is not required by using the impression material.
BACKGROUND: Bradyarrhythmias, requiring pacemaker (PM) implantation, are common complications following orthotopic heart transplantation (HTx). Currently used heart transplantation methods are primarily the bicaval technique and the total heart transplantation technique. The aim of the study was to assess the incidence and risk factors, including donor parameters, of conduction disorders requiring pacing after HTx.
METHODS: A population of 111 (52 ± 13 years, 91 (82%) men) heart recipients was divided into a group requiring PM implantation post-HTx and a group not requiring PM. We compared groups in terms of donor parameters, time of graft ischemia, transport and transplantation, and surgical techniques as the potential risk factors for significant bradyarrhythmias.
RESULTS: Ten of 111 patients with HTx (9%) required PM implantation. The indication in 7 cases was sinus node dysfunction (SND), in 3 patients it was complete atrioventricular block (AV-block). In the PM group, the age of 48 ± 6 vs 40 ± 11 years (P = .0227) and the body mass index (BMI) 28 ± 3 vs 26 ± 4 kg/m2 (P = .0297) of the donor were significantly higher. There was no influence of organ transport time, ischemia time, and transplantation time. All patients requiring PM implantation were transplanted using the bicaval anastomosis: 10 (100%) vs 71 (70%) in the group not requiring PM (P = .044).
CONCLUSIONS: The need for PM implantation post-HTx despite using new techniques is still common, especially in the group operated with the bicaval method. In addition, higher donor's age and BMI are risk factors of PM implantation, what is of importance as qualification criteria of donor hearts have been gradually extended.